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Objectives: The objective of this study was to compare the promotional strate-
gies of life style drugs (LSD) with non-lifestyle drugs (NLSD) by content analyzing 
print advertisements. MethOds: 142 print advertisements were analyzed to see 
how LSD and NLSD ad messages differed with respect to rational appeals, emo-
tional appeals and readability. Mann-Whitney U test was performed to compare 
the two groups of drug advertisements with respect to the type of promotional 
claims. Descriptive statistics were computed to summarize data pertaining to 
different ad features. The dataset was composed of 64 LSD advertisements and 
78 NLSD advertisements. Inter- rater reliability was measured by Cohen’s Kappa 
for two raters and was found to be adequate for all the variables used in the 
instrument. Results: Significant differences were observed between LSD and 
NLSD ads with respect to both emotional appeals (p= 0.000) and rational appeals 
(p= 0.000) based on Mann-Whitney U test. LSD ads focused more on emotional 
appeals while NLSD ads were heavy on rational content. A logistic regression 
analysis revealed likelihood estimates for ad claims appearing in the two groups. 
Readability calculated by Gunning-Fog Index for LSD’s was 8.84 and for NLSD’s 
was 11.56. Flesch-Kincaid grade level for LSD and NLSD was found to be 7.65 
and 10.73, respectively, indicating increased complexity of language in NLSD 
ads, which was mostly reflecting of the greater use of technical scientific lan-
guage. cOnclusiOns: The two groups of ads clearly differed with respect to 
type of content, presentation, structure and complexity as well as promotional 
strategies adopted. Rational appeals were more predictive of NLSD ad type while 
emotional appeals were predominant in LSD ads.
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Objectives: Annually, over 1 million people in the U.S. undergo hip or knee replace-
ments. Registries provide one mechanism to understand the benefits and risks 
of joint replacement in specific populations or care settings. Although countries 
such as Australia and Sweden have successfully established centralized JRRs, the 
U.S. has not. Avalere analyzed the diverse landscape of U.S. JRRs to determine 
the feasibility of creating one coordinated, national JRR for post-market surveil-
lance. MethOds: Avalere identified JRRs in the U.S. through the International 
Consortium of Orthopaedic Registries participants’ list, PubMed searches, abstract 
reviews, and web searches. Using publicly available sources, characteristics of each 
registry were recorded in a table. Avalere assessed this data to better understand 
the feasibility of harmonizing these registry efforts. Results: In total, 25 JRRs were 
identified: 3 national, 4 state, and 18 local. Established between 1967 and 2011, the 
registries spanned 14 states with objectives including post-market surveillance, 
outcome improvement, research, provider feedback, and value-based purchasing. Of 
the 20 registries with enrollment information, 15 enrolled 1-10 hospitals, 4 enrolled 
11-50 hospitals, and 1 enrolled more than 200 hospitals. One registry collected only 
Level I data; 2 collect Levels I-II; 9 collect Levels I-III; and 2 collect Levels I-IV; 11 
registries did not have data level collection information. Registry funding sources 
were self-funded (n= 7), publicly funded (n= 1), private payer (n= 1), and a combina-
tion (n= 2). cOnclusiOns: U.S. registries typically are established to serve the needs 
of their operating organization, which influences factors such as the registry’s mis-
sion, recruitment efforts, and data level collected. While the number of JRRs reflects 
stakeholders’ recognition of their value, the disparate (and sometimes competing) 
nature of efforts may pose challenges to the creation of a national JRR that can 
coordinate existing registries, ensure high quality data collection, and facilitate 
early surveillance to support federal regulatory needs.
HealtH care use & POlicy studies – Prescribing Behavior & treatment 
guidelines
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Objectives: Continuous, indiscriminate and excessive use of antimicrobial agents 
leads to emergence of antimicrobial-resistant organisms. Antimicrobial resistance 
substantially raises health care costs and influences patient outcomes (morbidity 
& mortality). There is a dearth of data available on appropriateness of parenteral 
antimicrobial therapy in the ICUs, especially in Indian settings. This study involves 
applying the GAAT criteria to assess the antimicrobial use. MethOds: This pro-
spective observational study was carried out in the intensive care units of a public 
teaching hospital over a period of 12 weeks. All the relevant data was recorded in a 
pre-designed standardized performa and analyzed. The patients were followed for 
first 7 days of ICU stay and the changes made in the treatment regimen were care-
fully evaluated. Parenteral antimicrobial therapy was assessed for appropriateness 
using GAAT. Intravenous antimicrobial therapy was considered appropriate if two 
or more of the GAAT criteria were met. Results: 85 ICU patients’ records were 
screened during the study period. Out of total 85 patients, 44 patients were male 
while remaining 41 were females. Of these, 74 patient records were found to have 
complete data for studying GAAT criteria. The parenteral antimicrobial therapy was 
found to be appropriate in 61 patients (82%), as per GAAT criteria. cOnclusiOns: 
Parenteral antimicrobial therapy, as per GAAT, in this study was appropriate in 82% 
of the patients. This is a preliminary study, future large scale studies should be car-
ried out over a longer period of time to draw any logical conclusion.
Canadian Agency for Drugs and Technologies in Health is funding initiatives such 
as the Canadian Platform To increase Usage of Real-world Evidence (CAPTURE) 
project in which physicians collaborate on gathering RWD to inform and improve 
standard health care practices. Finally, some US hospitals are leveraging the RWD 
they generate to optimize clinical and economic outcomes for their populations. 
Additionally, US payers are funding comparative effectiveness studies in crowded 
markets with costly assets and generic competition. cOnclusiOns: There is a 
need to monitor HTA agencies’ use of RWD to optimize access of the right treat-
ments to the right patients. There is also a need to approach evidence generation 
in a systematic manner to differentiate assets beyond approval and initial P&R 
as well as to generate evidence only for those gaps that will impact health care 
decisions.
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Objectives: As part of the Ontario Government’s health system funding reform ini-
tiative, the Evidence Development and Standards division at Health Quality Ontario 
(HQO) was tasked with developing episodes of care consisting of evidence-based, 
best practice recommendations. The HQO clinical handbooks span both medical 
and surgical conditions, in acute care and community based settings, and include 
between 25 and 100 recommendations each. The objective is to describe HQO’s 
methodology for developing evidence-based recommended best practices for epi-
sodes of care within the rapid timelines of the government mandated funding 
reform. MethOds: Over a 1-year period, the method for deriving evidence-based 
recommended practices was systematically and iteratively developed by HQO clini-
cal epidemiologists in collaboration with methodologists, clinical experts and stake-
holders. Results: The resulting approach for applying evidence to best practice 
recommendations included consideration of various evidence sources and consen-
sus from expert panels which were formed for each of the clinical topics. Preference 
was given to existing Ontario Health Technology Assessment Committee (OHTAC) 
recommendations as these are developed using a decision-making framework that 
considers the clinical benefit offered by a health intervention, in addition to value 
for money; societal and ethical considerations; and economic and organizational 
feasibility. Where OHTAC recommendations did not exist, international guidelines 
were reviewed and selected based on their contextual relevance and assessment 
of their rigor of development using the AGREE II instrument. Uncertainty or con-
flict between the guidelines, or by the expert panel members, was addressed with 
systematic evaluations of the literature through rapid reviews and evidence-based 
analyses. cOnclusiOns: While continually evolving to balance thoroughness and 
timeliness of evidence, HQO has developed a method of deriving episode of care 
recommended best practices set on an evidentiary base within a time-constrained 
government mandate.
HealtH care use & POlicy studies – Patient registries & Post-Marketing 
studies
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Objectives: To assess the currently perceived benefits and barriers of post-
marketing payer-manufacturer outcomes study collaborations by US payers and 
pharmaceutical manufacturers. MethOds: Regional and national US payers and 
pharmaceutical manufacturers with experience in collaborative post-marketing 
outcomes study endeavors were invited to participate in an hour-long telephone 
survey. The survey consisted of questions regarding their perceptions on the benefits 
and barriers of potential post-marketing outcomes study collaborations, as well 
as attributes of potential collaborators, studies, products or diseases that would 
be most highly valued. Descriptive statistics were used to characterize the survey 
responses. Results: A total of 12 payers and four pharmaceutical manufacturer 
representatives participated in the survey. Payers most often mentioned that the 
greatest benefit to partnering with manufacturers was the value manufacturers 
bring in terms of expertise and resources (58%). Benefits manufacturers identified 
included demonstrating consistency in outcomes data relative to randomized clini-
cal trial data and effectiveness in real-world populations. The two most commonly 
cited barriers by payers regarding participation in these post-marketing outcomes 
research collaborations included misaligned incentives (58%) and resource inten-
siveness (58%). The manufacturers felt that payers are generally wary of these types 
of collaborations due to possible perceptions of influence, and noted that payers 
are usually only willing to engage and focus on high-budget impact projects and 
collaborations. Payers’ most important consideration when selecting a pharma-
ceutical partner for outcomes studies was the willingness of the manufacturer to 
compromise and align on objectives (42%). Manufacturers agreed that alignment on 
objectives and expectations is critical for a successful partnership. cOnclusiOns: 
As competition in the pharmaceutical marketplace increases and recent US health 
care reform moves forward, payer-manufacturer post-marketing outcomes research 
collaborations will be increasingly critical as a demonstration of value to all stake-
holders.
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rity (42%), patient confirmation accuracy (73%), the correct rate of administration 
time (47%) and the correct rate of drug administration (57%). More than half of 
pharmacists and nurses complain the system wasn’t stable (53%, 69%) and poor bar-
code sensitivity (47%, 64%). The ratio of medication error was significantly reduced. 
(0.18%±0.042%, 0.12%±0.039%, P value < 0.05, n= 12) From Oct 2nd to Nov 15th in 2012, 
we received 469 phone calls. The average of tracing call for drugs is 1.67 times every 
hour. cOnclusiOns: Though some system problems may annoy hospital staffs, 
BCMA system could increase the accuracy of recognizing drugs, patients and tracing 
drugs. BCMA system also could significantly improve patient safety.
HealtH care use & POlicy studies – regulation of Health care sector
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Objectives: ERP is the practice of using pharmaceutical prices in several countries 
to derive a price benchmark in a given country and could be used as the main 
criteria for pricing decisions or merely as supportive information. It is a widely 
used financing method worldwide and in Europe; by 2012, all EU-countries except 
UK and Sweden used ERP in some form. Turkey applies ERP as the main pricing 
criteria since 2004. This analysis aims to elaborate the Turkish ERP system with its 
effects on the countries referring Turkey. MethOds: ERP systems of Turkey and 
countries referring Turkey have been analyzed. Results: Turkish reference basket 
is composed of Greece, Italy, France, Spain and Portugal, whose prices are rela-
tively lower than the European-average, plus import and manufacturer countries 
of the product. Lowest basket price sets the price-ceiling for reimbursed products, 
while highest can be taken for non-reimbursed products. Reference prices are sub-
ject to an exchange rate, fixed by Ministry of Health at approximately 40% below 
the actual rate. Consequently, Turkish prices are almost 44% of the lowest-priced 
European-country. Among the countries referring Turkey, Russia and S.Arabia are 
the most significant markets with their size and growing potentials. Additionally, 
Egypt, Macedonia, Morocco, Oman and Iran refer Turkey. cOnclusiOns: Although 
countries referring Turkey have large reference baskets, low Turkish prices could still 
be considered as a suppressing factor on prices in these countries. Furthermore, 
significant price changes especially in Russia and S.Arabia would possibly cause 
a second wave in some CIS and Middle East countries respectively, as they would 
adjust their prices within 6-12 months accordingly. Multinational companies con-
sider this domino effect seriously and usually arrange launch sequencing to avoid 
inoperably-low-prices and secure the most-promising-markets. Consequently, 
innovative products’ price levels and availability might occasionally be affected 
negatively in Turkey and further in countries referring Turkey.
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Objectives: In July 2012, the European Medicines Agency (EMA) established the 
Pharmacovigilance and Risk Assessment Committee (PRAC). The PRAC recommends 
and advises on any questions of pharmacovigilance activities related to a medi-
cine for human use and on risk management systems. This study describes PRAC’s 
activities to date. MethOds: Meeting minutes since July 2012 were retrieved from 
the EMA website. The PRAC received questions attributed to seven categories: EU 
referral procedures for safety reasons, signals assessment and prioritization, risk 
management plans (RMPs), assessment of periodic safety update reports (PSURs), 
post-authorisation safety studies (PASS), product-related pharmacovigilance 
inspections, and other safety issues for discussion requested by the Committee 
for Medicinal Products for Human Use (CHMP) or Member States (MS). Results: 
There were 13 meeting minutes available (July 2012 – October 2013), containing1077 
questions/requests with/without a formal decision-making phase [149 (13.9%) in 
2012, 928 (86.2%) in 2013]. Three request types comprise nearly 80% (n= 860): signal 
assessment and prioritization [n= 140 (13%), 50 (4.7%) in 2012, 90 (8.4%) in 2013], 
RMPs [n= 416 (38.7%), 48 (4.5%) in 2012, 368 (34.2%) in 2013], and PSURs [n= 304 
(28.2%), 20 (1.8%) in 2012, 284 (26.4%) in 2013]. PRAC outputs were recommenda-
tions or advice. In 2012, there were 46 recommendations for 35 new signal assess-
ments requests. Recommendations regarding new signals were made either to the 
Marketing Authorization Holder (MAH) (n= 32) (e.g., submit a cumulative review of 
dermatomyositis within 30 days), the EMA (n= 6) (e.g., review cases of dermatomy-
ositis and report back), the PRAC rapporteur (n= 7) (e.g., assess the UK cases in the 
ongoing PSUR procedure) or the MS (n= 1) (e.g., UK to provide a report on the nicotinic 
receptor mutation). cOnclusiOns: After an initial “running-in period”, the PRAC 
appears to be fulfilling its mandate. PRAC operations should be evaluated in terms 
of success (i.e., impact of decisions).
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Objectives: This article makes a review on the historical evolution of China’s drug 
regulatory system and provides some reflections and policy implications for the 
reform of the present system. MethOds: This study is based on literature review 
and publicly available data by searching electronic databases and official web pages 
of Chinese government on the internet. Results: China’s drug regulatory system 
has experienced complicated process of evolution. During the period of planned 
economy China had no independent drug regulatory system. The way to control 
the quality and safety of pharmaceutical products was to take full control of every 
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Objectives: Medication oversupply is an important problem which causes unnec-
essary avoidable health care costs. There are some studies determining magnitude 
and financial loss due to medication oversupply in western countries, they may not 
be applicable for Asia-pacific countries. This study aims to determine the preva-
lence, financial loss, and patterns of medication oversupply and factors associated 
with oversupply in Thailand. MethOds: A retrospective database analysis was 
conducted. Patients visiting out-patient department of 3 hospitals and receiving 
at least 2 prescriptions within 6 months were included. The modified medication 
possession ratio (MPRm) was used to determine the medication supply. Patients 
having MPRm> 1.20 were defined as medication oversupply. The measures were 
prevalence of medication oversupply, the number of oversupplied medications, 
and financial loss due to medication oversupply. Analyses were stratified by type 
of hospitals. A mixed regression model was used to determine factors associated 
with prevalence medication oversupply. Results: A total of 99,743 patients were 
included. Patients were on average 49.7±21.2 years of age, 42.8% were male. Around 
13.4% of all patients had medication oversupply. Patients in regional hospital had 
higher prevalence of medication oversupply than patients in district hospital (13.8% 
VS 8.2%). Patients under civil servant medical benefit schemes (CSMBS) (13.6%) 
had the highest prevalence of medication oversupply. The total financial loss due 
to medication oversupply was $189,024 per year. The average financial loss due 
to medication oversupply was $1.9±19.0 per patient/year. Patients under CSMBS 
was highest average financial loss (2.6±23.2 $/patient/year). Age, gender, health 
insurance schemes, and number of medications the patients received were factors 
associated with medication oversupply. cOnclusiOns: Medication oversupply is 
an important problem for the health system. Patients receiving care from regional 
hospital had higher likelihood of medication oversupply. Policy-makers may con-
sider developing policies for preventing medication oversupply.
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Objectives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. MethOds: To understand trends in use of health economic informa-
tion we conducted targeted search for clinical guidelines, expert recommendations, 
and consensus statements with specific mention of “cost” or “economic” or related 
terms. A systematic literature search was undertaken for the databases Pubmed, 
Google Scholar and Cochrane. The guidelines published between 2003-2012 were 
included. For guidelines which met the search criteria, data was collected for the 
name of the authors, indication, year of publication, country/region, and context 
of use of cost/economic evidence. Results: Sixteen clinical guidelines published 
between 2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. For 
indication, 3 out of 16 guidelines were for diabetes, while the rest were for different 
indications. In these 16 guidelines “cost effectiveness” was mentioned 14 times, 
either referencing cost-effectiveness data or to mention the importance of such data 
for selecting treatment options. The guidelines commonly cite high cost of disease 
or high economic burden as one of the considerations for developing new recom-
mendations (11 out of 16). Another term that was commonly used by these guide-
lines was “cost-benefit,” which was mentioned 5 times in these guidelines. Notably, 
QALY was rarely mentioned (1 out of 16 times) in these guidelines. cOnclusiOns: 
This analysis suggests that some clinical experts groups are increasingly showing 
willingness to use and incorporate health economic information for developing 
new recommendations
HealtH care use & POlicy studies – Quality of care
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Objectives: To analyze the current usage of BCMA enforced by the pharmacists 
and nurses at a medical center in Taiwan, we collected data including of the overall 
system satisfaction, ratio of medication errors and phone calls for tracking stat 
drugs. MethOds: The overall system’s satisfaction questionnaire for nurse (n= 89) 
and pharmacist (n= 30) was designed by 8 experts using content validity index (CVI). 
We have collected medication error ratio for one year in order to evaluate patients’ 
safety before and after using BCMA system. We also collected the numbers of phone 
calls for tracking stat drugs during Oct 2nd to Nov 15th in 2012. Results: In phar-
macists’ satisfaction questionnaire, they agree BCMA system can help them rec-
ognize drugs (60%), reduce medication errors (53%) and check drug delivery (90%). 
But they also think BCMA has increased workload (57%). In nurses’ satisfaction 
questionnaire, they agree BCMA system can help them increase case data’s integ-
